KRAS and colorectal carcinoma: Cetuximab presents relatively great therapeutic effect only among KRAS wide-type CRC patients while the KRAS mutant-type CRC patients show cetuximab resistance [12], for mutant KRAS and downstream pathways are activated and the tumor cell proliferates constantly.